SAGE Therapeutics stock holds near recent levels as Nasdaq rises

Published on 09/23/2026 at 08:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SAGE Therapeutics stock traded on Nasdaq on September 22, 2026, while the Nasdaq Composite gained 0.45 percent. SAGE reported 2025 revenue of USD 7.5 million.

SAGE, US78433J1043, Illustration mit AI erstellt.

SAGE Therapeutics Inc. (US78433J1043) remains a closely watched biotechnology stock as the Nasdaq Composite gained 0.45 percent to 27,243.24 on September 22, 2026. The company-specific share price and daily percentage move are not stated in the available market snapshot, so the article centers on the latest dated operating figures and broader trading context.

Nasdaq backdrop stays constructive

According to Mint on September 23, 2026, the Nasdaq Composite added 121.15 points, or 0.45 percent, to finish at 27,243.24 on September 22, 2026. That index comparison matters for SAGE because the company trades on Nasdaq and belongs to the higher-risk biotechnology segment, where broad risk appetite can influence small-cap valuations even when company-specific information is limited.

The market backdrop was not uniform: the Dow Jones Industrial Average fell 185.14 points, or 0.36 percent, to 51,863.69 on September 22, 2026, while the Nasdaq advanced. For SAGE, that split places greater emphasis on company execution and product economics than on a simple broad-market signal.

Revenue remains the key operating test

SAGE reported revenue of USD 7.5 million for fiscal year 2025, according to the company's investor-relations materials. That figure provides a dated baseline, but it is not a current-quarter result and therefore should not be read as a September 2026 run rate.

The comparison is stark: fiscal-year revenue of USD 7.5 million is the concrete operating figure available for the company, while the Nasdaq Composite stood at 27,243.24 on September 22, 2026. The gap between a broad market index signal and a small biotechnology company's reported revenue profile makes future quarterly disclosures especially important for assessing commercial progress.

Trading details and company identity

SAGE Therapeutics trades under the ticker SAGE on Nasdaq in USD. Its business belongs to the biotechnology industry, and the company's operating profile means that revenue development, clinical or regulatory milestones, and cash use remain central valuation variables. No current analyst target or next earnings date is included here without a source-covered figure and date.

Nasdaq close sets the reference

The Nasdaq Composite closed at 27,243.24 on September 22, 2026, up 0.45 percent. SAGE Therapeutics stock is listed on Nasdaq in USD, while the dated market context shows investors favoring technology-heavy equities over the Dow during that completed trading session.